Oxy-PICU Neurodevelopmental Follow-up Study
Oxy-PICU ND
2 other identifiers
observational
556
0 countries
N/A
Brief Summary
Background to the research: Each year around 20,000 children are admitted to paediatric intensive care units (PICUs) in the UK. Of these children, \~75% will receive support from a breathing machine (or ventilator) in combination with additional oxygen. We recently completed the NIHR funded Oxy-PICU randomised clinical trial (RCT) - a study that compares one treatment against another to determine which is best. The Oxy-PICU RCT investigated whether children in PICU who are receiving help from a ventilator with additional oxygen, should have their oxygen levels kept at a lower level or higher level which currently used in the NHS. We found that aiming for lower oxygen levels was better and resulted in a small but significant reduction in the number of days children spent on machines or died at 30 days. While small, this result would have a large and important impact for patients and their families and may have important cost savings for the NHS. However, while in the short-term targeting lower oxygen levels appears better, the effects on children's longer-term development are unknown. Knowing this is important to fully inform doctors and nurses about the effects of aiming for lower oxygen levels, and help the results of Oxy-PICU be applied throughout the NHS. Aim of the research: This research aims to complete longer-term follow-up of children included in the Oxy-PICU RCT. We will look at the effect of aiming for lower oxygen levels compared to higher oxygen levels on longer-term developmental milestones. Research plan: We will invite 1,112 parents of children included in the Oxy-PICU RCT by email and post to take part. We will arrange a telephone interview with the parent(s) who agree to participate. A trained researcher will use standard questionnaires to measure important issues. They'll establish if the children are meeting their developmental milestones and learn about their health related quality of life. After the interview we will provide a report to the parents detailing their child's development. We anticipate 50% of those approached will agree to take part in this study. This will allow us to detect important differences in developmental milestones in children treated with lower oxygen levels. Patient and public involvement: PPI has been essential throughout Oxy-PICU. Our PPI co-applicant has been involved in Oxy-PICU from the start as a key member of the study team and will continue to help oversee all aspects of this research. We will also appoint a parent advisory group to provide additional PPI input into the study processes. Knowledge mobilisation: Outputs from the neurodevelopmental follow-up will be specifically targeted to the key stakeholders including patients/parents, clinicians and policy makers. Outputs for patients/parents and the public will be co-produced with our PPI representatives.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2025
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
December 11, 2024
CompletedFirst Posted
Study publicly available on registry
December 16, 2024
CompletedStudy Start
First participant enrolled
January 1, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
September 1, 2026
ExpectedDecember 16, 2024
December 1, 2024
5 months
December 11, 2024
December 11, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Neurodevelopmental function defined as the overall adaptive behaviour score assessed using the Vineland Adaptive Behaviour Scales, third edition (VABS-3).
Overall adaptive behaviour score obtained from the Vineland Adaptive Behaviour Scales, third edition (VABS-3) questionnaire.
4 years post randomization into the Oxy-PICU RCT (ISRCTN92103439)
Secondary Outcomes (2)
VABS-3 domain scores
4 years post randomization into the Oxy-PICU RCT (ISRCTN92103439)
Health related quality of life
4 years post randomization into the Oxy-PICU RCT (ISRCTN92103439)
Study Arms (2)
Conservative oxygenation
Patients that have previously received treatment in paediatric intensive care with conservative oxygenation
Liberal oxygenation
Patients that have previously received treatment in paediatric intensive care with liberal oxygenation
Interventions
Patients that were previously randomised to receive conservative oxygenation while in paediatric intensive care
Patients that were previously randomised to receive conservative oxygenation while in paediatric intensive care
Eligibility Criteria
Parents/caregivers of children enrolled into Oxy-PICU and who provided consent to be contacted about future related research.
You may qualify if:
- Parent or caregiver of child included in the Oxy-PICU RCT;
- Provided consent to be contacted about future research;
- Living with child; and
- Child/young person survival status confirmed.
You may not qualify if:
- None.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- FAMILY BASED
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
December 11, 2024
First Posted
December 16, 2024
Study Start
January 1, 2025
Primary Completion
June 1, 2025
Study Completion (Estimated)
September 1, 2026
Last Updated
December 16, 2024
Record last verified: 2024-12